New drug

New drug
VSY Biotechnology GmbH has announced that a new drug named TR-C 19 has been developed to treat COVID-19 by the company’s research centre. Studies have shown that TR-C 19 can neutralise the virus isolated under laboratory conditions, according to VSY. The drug is now at the authority approval stage for usage on voluntary COVID-19 patients and clinical trial. “[This] is one of the most meaningful projects that we have been developing,” said Dr Ercan Varlibas, Chairman of the Board of Directors of VSY Biotechnology GmbH. https://www.vsybiotechnology.com/
Latest Articles
Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Picture This: Photo Contest Winners

ESCRS 2025 Refractive and Cataract Photo Contest winners.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Nutrition and the Eye: A Recipe for Success

A look at the evidence for tasty ways of lowering risks and improving ocular health.

Read more...

New Award to Encourage Research into Sustainable Practices

Read more...

Sharing a Vision for the Future

ESCRS leaders update Trieste conference on ESCRS initiatives.

Read more...

Extending Depth of Satisfaction

The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.

Read more...

Conventional Versus Laser-Assisted Cataract Surgery

Evidence favours conventional technique in most cases.

Read more...